SHPH
Shuttle Pharmaceuticals Holdings, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$3.49
+3.25%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.32
From 52W high−84.96%
Volume16447.00
Market cap$3.58M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$3.32
From 52W high
−84.96%
Volume
16447.00
Market cap
$3.58M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
45.8
MomentumView details →
1D Return
+3.25%
YTD Return
+92.00%
SummaryUpdated Mar 1, 2026
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Rockville, Maryland. The company went public in August 2022 and focuses on developing specialized cancer treatments that enhance the effectiveness of radiation therapy. Shuttle Pharmaceuticals operates through its subsidiary, Shuttle Pharmaceuticals, Inc., and is currently advancing two key drug candidates through clinical trials to address some of the most challenging cancer types including brain tumors, sarcomas, and pancreatic cancer.
Similar companies
Latest newsMore news →
Shuttle Pharmaceuticals Holdings, Inc. issued shares of common stock upon conversion of its Series B-1 and B-2 Preferred Stock and issued warrants and pre-funded warrants to purchase common stock in an unregistered private placement.4d agoShuttle Pharmaceuticals Holdings, Inc. amended its merger agreement with United Dogecoin Inc., reducing the number of Mining Rigs required to satisfy the Milestone Event from 2,000 to 500.19d agoShuttle Pharmaceuticals Holdings received a NASDAQ noncompliance letter for failing to file its Form 10-Q for the quarter ended June 30, 2026 by the required due date.23d ago